Home Cart Sign in  
Chemical Structure| 1061353-68-1 Chemical Structure| 1061353-68-1

Structure of PND-1186
CAS No.: 1061353-68-1

Chemical Structure| 1061353-68-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PND-1186 is a potent FAK inhibitor with IC50 of 1.5 nM.

Synonyms: VS-4718; SR-2516; SR-2156

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PND-1186

CAS No. :1061353-68-1
Formula : C25H26F3N5O3
M.W : 501.50
SMILES Code : O=C(NC)C1=CC=CC=C1NC2=CC(NC3=CC=C(N4CCOCC4)C=C3OC)=NC=C2C(F)(F)F
Synonyms :
VS-4718; SR-2516; SR-2156
MDL No. :MFCD28125506
InChI Key :IGUBBWJDMLCRIK-UHFFFAOYSA-N
Pubchem ID :25073775

Safety of PND-1186

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of PND-1186

RTK
cytoskeleton

Isoform Comparison

Biological Activity

Target
  • FAK

    FAK, IC50:1.5 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01849744 Non Hematologic Cancers|Metast... More >>atic Cancer Less << PHASE1 TERMINATED 2025-06-17 HonorHealth Research Institute... More >>, Scottsdale, Arizona, 85258, United States|Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|Florida Cancer Specialists, Sarasota, Florida, 34232, United States|Washington University School of Medicine, Division of Oncology, Saint Louis, Missouri, 63110, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States Less <<
NCT02215629 Relapsed or Refractory Acute M... More >>yeloid Leukemia|Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Less << PHASE1 WITHDRAWN 2025-11-16 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.99mL

0.40mL

0.20mL

9.97mL

1.99mL

1.00mL

19.94mL

3.99mL

1.99mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories